Small-molecule inhibitors (erlotinib, gefitinib, and afatinib) and a monoclonal antibody (cetuximab) targeted to EGFR have been used for treatment of lung, colorectal, head and neck, and pancreatic cancers. Here, EGFR is linked to pancreatic neoplasm.